


AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior claims presented in the application.

1. (Currently amended) A compound substituted aniline derivative of formula I



wherein

\mathbf{U} is \mathbf{O} , \mathbf{S} or $\mathbf{N}\mathbf{R}^2$;

\mathbf{s} is 0 or 1;

\mathbf{X} is \mathbf{CO} or \mathbf{SO}_2 ;

Z is O, S or NR⁴, wherein R⁴ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl and hydroxy-C₃₋₈-cycloalk(en)yl;

q is 0 or 1;

R¹ and **R**^{1'} are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, acyl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl and halo-C₃₋₈-cycloalk(en)yl;


R² is selected from the group consisting of hydrogen, halogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-C₃₋₈-cycloalk(en)yl, acyl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-cycloalk(en)yl and cyano; provided that when **R**² is halogen or cyano, then **s** is 0;






when **s** is 1 and **U** is NR^{2'} then **R**^{2'} is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-C₃₋₈-cycloalk(en)yl, acyl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl and halo-C₃₋₈-cycloalk(en)yl; or **R**² and **R**^{2'} together with the nitrogen atom to which they are attached form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom;

R³ is selected from the group consisting of C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-C₃₋₈-cycloalk(en)yl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl and halo-C₃₋₈-cycloalk(en)yl;

and

Y represents a group of formulae VI, VII, VIII, IX or XXX:





wherein

~~the line represents a bond attaching the group represented by Y to the nitrogen atom;~~

W is O or S;

a is 0, 1, 2 or 3;

b is 0, 1, 2, 3 or 4;

c is 0 or 1;

d is 0, 1, 2 or 3;

e is 0, 1 or 2;

f is 0, 1, 2, 3, 4 or 5;

g is 0, 1, 2, 3 or 4;

h is 0, 1, 2 or 3; and

each **R**⁵ is independently selected from the group consisting of a C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, Ar, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar-C₁₋₆-alk(en/yn)yl, acyl, C₁₋₆-alk(an/en/yn)yloxy, halogen, halo-C₁₋₆-alk(en/yn)yl, -CO-NR⁶R⁶, cyano, nitro, -NR⁷R⁷, -S-R⁸, -SO₂R⁸ and SO₂OR⁸, or two R⁵ substituents together with the carbon atoms to which they are attached form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms;

R⁶ and **R**⁶' are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl and Ar;

R⁷ and **R**⁷' are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar and acyl; and

R⁸ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar and -NR⁹R⁹; wherein **R**⁹ and **R**⁹' are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; with the provisos that when **R**⁵ is SO₂OR⁸ then **R**⁸ is not -NR⁹R⁹' and when **R**⁵ is SO₂R⁸, then **R**⁸ is not a hydrogen atom;

or salts thereof;

with the proviso that the compound of formula I is not:

N-[4-[(4-aminophenyl)amino]methyl]phenyl]-acetamide;

N-[4-[[4-amino-2-methylphenyl)amino]methyl]phenyl]-acetamide;
N-[4-[[4-amino-3-methylphenyl)amino]methyl]phenyl]-acetamide;
2-[[[4-(acetylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)-benzamide;
N-[4-[[3,4,5-trimethoxyphenyl)amino]methyl]phenyl]-acetamide;
N-[4-[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2- naphthalenyl)amino]methyl]phenyl]-acetamide;
N-[4-[[3-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]- acetamide;
N-[4-[[2-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]-acetamide;
N-[4-[[4-amino-3,5-dichlorophenyl)amino]methyl]phenyl]- acetamide;
N-[4-[[2,4-diamino-6-quinazolinyl)amino]methyl]phenyl]- acetamide; or
N-[4-[[2,4-diamino-6-quinazolinyl)amino]methyl]phenyl]- acetamide.

2. (Currently amended) A compound according to ~~Claim~~ claim 1, wherein \mathbf{R}^1 and $\mathbf{R}^{1'}$ are independently selected from the group consisting of hydrogen and C_{1-6} -alk(en/yn)yl.
3. (Currently amended) A compound according to ~~Claim~~ claim 2, wherein at least one of \mathbf{R}^1 and $\mathbf{R}^{1'}$ is a hydrogen atom.
4. (Currently amended) A compound according to ~~any one of Claims 1-3~~ claim 1, wherein s is 1.
5. (Currently amended) A compound according to ~~any one of Claims 1-3~~ claim 1, wherein s is 0.

6. (Currently amended) A compound according to ~~any one of Claims 4-5~~ claim 1, wherein \mathbf{R}^2 is selected from the group consisting of hydrogen, $\text{C}_{1-6}\text{-alk(en/yn)yl}$, Ar and halogen, provided that when \mathbf{R}^2 is halogen, then \mathbf{s} is 0.
7. (Currently amended) A compound according to ~~Claim~~ claim 4, wherein \mathbf{U} is $\mathbf{N}\mathbf{R}^{2'}$ and at least one of \mathbf{R}^2 and $\mathbf{R}^{2'}$ is a hydrogen atom.
8. (Currently amended) A compound according to ~~Claim~~ claim 7, wherein both \mathbf{R}^2 and $\mathbf{R}^{2'}$ are hydrogen atoms.
9. (Currently amended) A compound according to ~~any one of Claims 1-8~~ claim 1, wherein \mathbf{X} is CO.
10. (Currently amended) A compound according to ~~any one of Claims 1-9~~ claim 1, wherein \mathbf{q} is 0.
11. (Currently amended) A compound according to ~~any one of Claims 1-9~~ claim 1, wherein \mathbf{q} is 1.
12. (Currently amended) A compound according to ~~Claim~~ claim 11, wherein \mathbf{Z} is an oxygen atom.
13. (Currently amended) A compound according to ~~any one of Claims 1-12~~ claim 1, wherein \mathbf{R}^3 is $\text{C}_{1-6}\text{-alk(en/yn)yl}$.
14. (Currently amended) A compound according to ~~any one of Claims 1-13~~ claim 1, wherein \mathbf{Y} represents a group of formulae **IX** or **XXX**.
15. (Currently amended) A compound according to ~~any one of Claims 1-14~~ claim 1, wherein each \mathbf{R}^5 is independently selected from the group consisting of a $\text{C}_{1-6}\text{-alk(en/yn)yl}$, $\text{C}_{3-8}\text{-cycloalk(en)yl}$, Ar, cyano, halogen, halo- $\text{C}_{1-6}\text{-alk(en/yn)yl}$ and $\text{C}_{1-6}\text{-alk(an/en/yn)yloxy}$ or two adjacent \mathbf{R}^5 substituents together with the carbon atoms to which they are attached form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms.


16. (Currently amended) A compound ~~according to any one of Claims 1-15, said compound being~~ selected from the group consisting of:

{2-Amino-4-[(4-tert-butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
(2-Amino-4-phenylaminomethyl-phenyl)-carbamic acid ethyl ester;
[2-Amino-4-(naphthalen-2-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;
[2-Amino-4-(p-tolylamino-methyl)-phenyl]-carbamic acid ethyl ester;
{2-Amino-4-[(4-trifluoromethylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(4-chlorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(3-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(4-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(2-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
[2-Amino-4-(biphenyl-4-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;
{2-Amino-4-[(2,4-difluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(4-methoxyphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(4-cyclohexylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
[2-Amino-4-(indan-5-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;
{2-Amino-4-[(4-isopropylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(4-butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Amino-4-[(2,4-dichlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Amino-4-[(2,3-dichlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Amino-4-[(3,5-dichlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Amino-4-[(3,4-dichlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Amino-4-[(3-trifluoromethylphenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Amino-4-[(3-fluoro-4-trifluoromethylphenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Amino-4-[(3,4-difluorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Amino-4-[(4-cyanophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[(4-fluoro-3-trifluoromethylphenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Amino-4-[(3-chloro-4-methylphenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Amino-4-[(3-chlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
[2-Amino-4-(m-tolylaminomethyl)phenyl]carbamic acid ethyl ester;
{2-Amino-4-[1-(4-chlorophenylamino)ethyl]phenyl} carbamic acid ethyl ester;
{2-Amino-4-[1-(4-trifluoromethylphenylamino)ethyl]phenyl} carbamic acid ethyl ester;
N-{2-Amino-4-[(3-fluorophenylamino)methyl]phenyl}-2,2-dimethylpropionamide;
{4-[(4-Chlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
{4-[(4-Trifluoromethylphenylamino)methyl]phenyl} carbamic acid ethyl ester;
{4-[1-(4-Chlorophenylamino)ethyl]phenyl} carbamic acid ethyl ester;
{4-[(4-Fluorophenylamino)methyl]-2-methylphenyl} carbamic acid ethyl ester;
{4-[(4-Chlorophenylamino)methyl]-2-methylphenyl} carbamic acid ethyl ester;
{2-Methyl-4-[(4-trifluoromethylphenylamino)methyl]phenyl} carbamic acid ethyl ester;
{4-[(3,4-Difluorophenylamino)methyl]-2-methylphenyl} carbamic acid ethyl ester;
{4-[(3-Fluorophenylamino)methyl]-2-methylphenyl} carbamic acid ethyl ester;
{2-Chloro-4-[(4-chlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Chloro-4-[(4-trifluoromethyl-phenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
{2-Chloro-4-[(4-fluorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Chloro-4-[(3-fluorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Chloro-4-[(3,4-dichlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
{2-Chloro-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl} carbamic acid ethyl ester;
{4-[(4-Chlorophenylamino)methyl]-2-fluorophenyl} carbamic acid ethyl ester;
{4-[(4-Chloro-3-fluorophenylamino)methyl]-2-fluorophenyl} carbamic acid ethyl ester;
{2-Fluoro-4-[(4-trifluoromethylphenylamino)methyl]phenyl} carbamic acid ethyl ester;
{4'-Dimethylamino-5-[(3-fluorophenylamino)methyl]biphenyl-2-yl} carbamic acid ethyl ester;
{4'-Dimethylamino-5-[(4-trifluoromethylphenylamino)methyl]biphenyl-2-yl} carbamic acid ethyl ester;

{4'-Chloro-5-[(3-fluorophenylamino)methyl]biphenyl-2-yl} carbamic acid ethyl ester;
{4'-Chloro-5-[(4-trifluoromethylphenylamino)methyl]biphenyl-2-yl} carbamic acid ethyl ester;
N-{4-[(4-chlorophenylamino)methyl]phenyl}butyramide;
N-{4-[(3,4-dichlorophenylamino)methyl]phenyl}butyramide;
N-{4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}butyramide;
N-{4[(4-fluoro-phenylamino)methyl]-2-methylphenyl}butyramide;
N-{4[(3-fluorophenylamino)methyl]-2-methylphenyl}butyramide;
N-{4-[(4-chlorophenylamino)methyl]-2-methylphenyl}butyramide;
N-{4-[(3,4-dichlorophenylamino)methyl]-2-methylphenyl}butyramide;
N-{4-[(4-chloro-3-fluorophenylamino)methyl]-2-methylphenyl}butyramide;
N-{2-chloro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}butyramide;
N-{2-chloro-4-[(4-fluorophenylamino)methyl]phenyl}butyramide;
N-{2-chloro-4-[(3-fluorophenylamino)methyl]phenyl}butyramide;
N-{2-chloro-4-[(4-chlorophenylamino)methyl]phenyl}butyramide;
N-{2-chloro-4-[(3,4-dichlorophenylamino)methyl]phenyl}butyramide;
N-{2-chloro-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}butyramide;
N-{2-fluoro-4-[(3-fluorophenylamino)methyl]phenyl}butyramide;
N-{4-[(4-chlorophenylamino)methyl]-2-fluorophenyl}butyramide;
N-{2-fluoro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}butyramide;
N-{4-[(3,4-dichlorophenylamino)methyl]-2-fluorophenyl}butyramide; and
N-{4-[(4-chloro-3-fluorophenylamino)methyl]-2-fluorophenyl}butyramide, [[.]]
or a salt thereof.

17. (Currently amended) A pharmaceutical composition comprising ~~one or more pharmaceutically acceptable carriers or diluents and a compound of the below formula I~~



wherein

U is O, S or NR²;

s is 0 or 1;

X is CO or SO₂;

Z is O, S or NR⁴, wherein R⁴ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl and hydroxy-C₃₋₈-cycloalk(en)yl;

q is 0 or 1;

R¹ and **R**^{1'} are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, acyl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl and halo-C₃₋₈-cycloalk(en)yl;




\mathbf{R}^2 is selected from the group consisting of hydrogen, halogen, $\text{C}_{1-6}\text{-alk(en/yn)yl}$, $\text{C}_{3-8}\text{-cycloalk(en)yl}$, $\text{C}_{3-8}\text{-cycloalk(en)yl-C}_{1-6}\text{-alk(en/yn)yl}$, Ar, $\text{Ar-C}_{1-6}\text{-alk(en/yn)yl}$, $\text{Ar-C}_{3-8}\text{-cycloalk(en)yl}$, acyl, hydroxy- $\text{C}_{1-6}\text{-alk(en/yn)yl}$, hydroxy- $\text{C}_{3-8}\text{-cycloalk(en)yl}$, halo- $\text{C}_{1-6}\text{-alk(en/yn)yl}$, halo- $\text{C}_{3-8}\text{-cycloalk(en)yl}$ and cyano; provided that when \mathbf{R}^2 is halogen or cyano then s is 0;






when s is 1 and \mathbf{U} is $\mathbf{N}\mathbf{R}^2$ then \mathbf{R}^2 is selected from the group consisting of hydrogen, $\text{C}_{1-6}\text{-alk(en/yn)yl}$, $\text{C}_{3-8}\text{-cycloalk(en)yl}$, $\text{C}_{3-8}\text{-cycloalk(en)yl-C}_{1-6}\text{-alk(en/yn)yl}$, Ar, $\text{Ar-C}_{1-6}\text{-alk(en/yn)yl}$, $\text{Ar-C}_{3-8}\text{-cycloalk(en)yl}$, acyl, hydroxy- $\text{C}_{1-6}\text{-alk(en/yn)yl}$, hydroxy- $\text{C}_{3-8}\text{-cycloalk(en)yl}$, halo- $\text{C}_{1-6}\text{-alk(en/yn)yl}$ and halo- $\text{C}_{3-8}\text{-cycloalk(en)yl}$; or \mathbf{R}^2 and \mathbf{R}^2 together with the nitrogen atom to which they are attached form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom;

\mathbf{R}^3 is selected from the group consisting of $\text{C}_{1-6}\text{-alk(en/yn)yl}$, $\text{C}_{3-8}\text{-cycloalk(en)yl}$, $\text{C}_{3-8}\text{-cycloalk(en)yl-C}_{1-6}\text{-alk(en/yn)yl}$, Ar, $\text{Ar-C}_{1-6}\text{-alk(en/yn)yl}$, $\text{Ar-C}_{3-8}\text{-cycloalk(en)yl}$, hydroxy- $\text{C}_{1-6}\text{-alk(en/yn)yl}$, hydroxy- $\text{C}_{3-8}\text{-cycloalk(en)yl}$, halo- $\text{C}_{1-6}\text{-alk(en/yn)yl}$ and halo- $\text{C}_{3-8}\text{-cycloalk(en)yl}$;

and

\mathbf{Y} represents a group of formulae VI, VII, VIII, IX or XXX:





wherein

~~the line represents a bond attaching the group represented by Y to the nitrogen atom;~~

W is O or S;

a is 0, 1, 2 or 3;

b is 0, 1, 2, 3 or 4;

c is 0 or 1;

d is 0, 1, 2 or 3;

e is 0, 1 or 2;

f is 0, 1, 2, 3, 4 or 5;

g is 0, 1, 2, 3 or 4;

h is 0, 1, 2 or 3; and

each **R**⁵ is independently selected from the group consisting of a C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, Ar, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar-C₁₋₆-alk(en/yn)yl, acyl, C₁₋₆-alk(an/en/yn)yloxy, halogen, halo-C₁₋₆-alk(en/yn)yl, -CO-NR⁶R⁶, cyano, nitro, -NR⁷R⁷, -S-R⁸, -SO₂R⁸ and SO₂OR⁸, or two R⁵ substituents together with the carbon atoms to which they are attached form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms;

R⁶ and **R**⁶' are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl and Ar;

R⁷ and **R**⁷' are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar and acyl; and

R⁸ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar and -NR⁹R⁹; wherein **R**⁹ and **R**⁹' are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; with the provisos that when **R**⁵ is SO₂OR⁸ then **R**⁸ is not -NR⁹R⁹' and when **R**⁵ is SO₂R⁸, then **R**⁸ is not a hydrogen atom;

or salts a pharmaceutically acceptable salt thereof;

and one or more pharmaceutically acceptable carriers or diluents,

with the proviso that the compound of formula I is not:



2-[[[4-(acetylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)-benzamide;

N-[4-[[3,4,5-trimethoxyphenyl]amino]methyl]phenyl]-acetamide;

N-[4-[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]amino]methyl]phenyl]-acetamide;

N-[4-[[3-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]- acetamide;
N-[4-[[2-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]-acetamide;
N-[4-[[4-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]- acetamide;
N-[4-[[4-amino-3,5-dichlorophenyl]amino]methyl]phenyl]- acetamide;
N-[4-[[2,4-diamino-6-quinazolinyl]amino]methyl]phenyl]- or
N-[4-[[2,4-diamino-6-quinazolinyl]amino]methyl]phenyl]- acetamide.

18. (Currently amended) A method of increasing ion flow in a potassium channel of a mammal, comprising administering to said mammal Use of a pharmaceutical composition one or more pharmaceutically acceptable carriers or diluents and a compound of the below formula I



wherein

U is O, S or NR²;

s is 0 or 1;

X is CO or SO₂;

Z is O, S or NR⁴, wherein R⁴ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl and hydroxy-C₃₋₈-cycloalk(en)yl;

q is 0 or 1;

R¹ and **R**^{1'} are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, acyl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl and halo-C₃₋₈-cycloalk(en)yl;


R² is selected from the group consisting of hydrogen, halogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-C₃₋₈-cycloalk(en)yl, acyl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-cycloalk(en)yl and cyano; provided that when **R**² is halogen or cyano then **s** is 0;






when **s** is 1 and **U** is NR^{2'} then **R**^{2'} is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-C₃₋₈-cycloalk(en)yl, acyl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl and halo-C₃₋₈-cycloalk(en)yl; or **R**² and **R**^{2'} together with the nitrogen atom to which they are attached form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom;

R³ is selected from the group consisting of C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar, Ar-C₁₋₆-alk(en/yn)yl, Ar-C₃₋₈-cycloalk(en)yl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, halo-C₁₋₆-alk(en/yn)yl and halo-C₃₋₈-cycloalk(en)yl;

and

Y represents a group of formulae VI, VII, VIII, IX or XXX:





wherein

~~the line represents a bond attaching the group represented by Y to the nitrogen atom;~~

W is O or S;

a is 0, 1, 2 or 3;

b is 0, 1, 2, 3 or 4;

c is 0 or 1;

d is 0, 1, 2 or 3;

e is 0, 1 or 2;

f is 0, 1, 2, 3, 4 or 5;

g is 0, 1, 2, 3 or 4;

h is 0, 1, 2 or 3; and

each **R**⁵ is independently selected from the group consisting of a C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, Ar, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar-C₁₋₆-alk(en/yn)yl, acyl, C₁₋₆-alk(an/en/yn)yloxy, halogen, halo-C₁₋₆-alk(en/yn)yl, -CO-NR⁶R⁶, cyano, nitro, -NR⁷R⁷, -S-R⁸, -SO₂R⁸ and SO₂OR⁸, or two R⁵ substituents together with the carbon atoms to which they are attached form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms;

R⁶ and **R**⁶' are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl and Ar;

R⁷ and **R**⁷' are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar and acyl; and

R⁸ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, Ar and -NR⁹R⁹; wherein **R**⁹ and **R**⁹' are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; with the provisos that when **R**⁵ is SO₂OR⁸ then **R**⁸ is not -NR⁹R⁹' and when **R**⁵ is SO₂R⁸, then **R**⁸ is not a hydrogen atom;

or salts thereof

for increasing ion flow in a potassium channel of mammal such as a human.

19. (Currently amended) Use according to Claim The method of claim 18 wherein administration of said compound is for the prevention, treatment or inhibition of a disorder or condition being responsive to an increased ion flow in a potassium channel, such disorder or condition is preferably a disorder or condition of the central nervous system.

20. (Currently amended) ~~Use according to Claim~~ The method of claim 19 characterized in that wherein the disorder or condition is a seizure disorder selected from the group consisting of seizure disorders such as convulsions, epilepsy and status epilepticus.
21. (Currently amended) ~~Use according to Claim~~ The method of claim 19 characterized in that wherein the disorder or condition is selected from the group consisting of neuropathic and migraine pain disorders such as allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy and neuropathic pain related to migraine.
22. (Currently amended) ~~Use according to Claim~~ The method of claim 19 characterized in that wherein the disorder or condition is an anxiety disorder selected from the group consisting of anxiety disorders such as anxiety, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, social phobia, performance anxiety, post traumatic stress disorder, acute stress reaction, adjustment disorders, hypochondriacal disorders, separation anxiety disorder, agoraphobia, specific phobias, anxiety disorder due to general medical condition and substance-induced anxiety disorder.
23. (Currently amended) ~~Use according to Claim~~ The method of claim 19 characterized in that wherein the disorder or condition is a neurodegenerative disorder selected from the group consisting of and neurodegenerative disorders such as Alzheimer's disease, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, AIDS induced encephalopathy and other infection related encephalopathies being caused by rubella viruses, herpes viruses, borrelia and by unknown pathogens, Creutzfeld Jakob disease, Parkinson's disease, trauma-induced neurodegenerations.
24. (Currently amended) ~~Use according to~~ The method of claim 19 characterized in that wherein the disorder or condition is a neuronal hyperexcitation state selected from the group consisting of neuronal hyperexcitation states such as in medicament withdrawal or by intoxication.

25. (New) The method of claim 18 wherein the mammal is a human.
26. (New) The method of claim 19 wherein the disorder or condition is a disorder or condition of the central nervous system.
27. (New) The method of claim 20 wherein the seizure disorder is selected from the group consisting of convulsions, epilepsy and status epileptus.
28. (New) The method of claim 21 wherein the neuropathic or migraine pain disorder is selected from the group consisting of allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy and neuropathic pain related to migraine.
29. (New) The method of claim 22 wherein the anxiety disorder is selected from the group consisting of anxiety, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, acute stress reaction, adjustment disorders, hypochondriacal disorders, separation anxiety disorder, agoraphobia, specific phobias, anxiety disorder due to general medical condition and substance-induced anxiety disorder.
30. (New) The method of claim 23 wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, AIDS-induced encephalopathy and other infection-related encephalopathies being caused by rubella viruses, herpes viruses, borrelia and by unknown pathogens, Creutzfeld-Jakob disease, Parkinson's disease, trauma-induced neurodegenerations.
31. (New) The method of claim 24 wherein the neuronal hyperexcitation state is due to medicament withdrawal or intoxication.